NBCC’s advocacy has resulted in more than $3.9 billion federal dollars for breast cancer research.
Breast cancer accounts for nearly a quarter of all cancers in women worldwide.
The DOD BCRP was created as a result of NBCC’s “$300 Million More” campaign to increase federal funding for breast cancer research.
The National Breast Cancer Coalition is proud to announce bipartisan support for a bill to waive onerous health care waiting periods for those with metastatic breast cancer.
Project LEAD 2022, Thank You for Joining Us, Tell Us Your Advocacy Story, And More!
We all want new treatments to “work” for breast cancer patients. For the National Breast Cancer Coalition (NBCC), that means the investigational therapy will significantly prolong overall survival (OS) without adverse impact on quality of life. We expect that the evidence of that benefit will be shown by well-designed, well-conducted prospective randomized clinical trials, sufficiently designed to support that result. Unfortunately, that has not been the case with TECENTRIQ® (atezolizumab) in first-line treatment of advanced or metastatic triple-negative breast cancer (TNBC).
Studies to date reveal mixed findings of the addition of CDK4/6 inhibitors in the early breast cancer setting, with two trials of palbociclib demonstrating no benefit and very early results in monarchE with abemaciclib showing a preliminary benefit of 3.5% absolute reduction in IDFS. The results from NATALEE (ribociclib) are not yet out.